Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Declines By 44.0%

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) saw a significant decrease in short interest in May. As of May 15th, there was short interest totalling 4,200 shares, a decrease of 44.0% from the April 30th total of 7,500 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 236,800 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price target on Armata Pharmaceuticals from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, May 19th.

Armata Pharmaceuticals Trading Down 12.4%

Shares of Armata Pharmaceuticals stock opened at $1.90 on Monday. The business has a 50 day moving average of $1.46. The stock has a market cap of $68.74 million, a PE ratio of -1.16 and a beta of 0.87. Armata Pharmaceuticals has a one year low of $0.90 and a one year high of $3.42.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.